<unk>  (commonly called<unk> , systematic name 2',3'-dideoxy-5-fluoro-3'-thiacytidine), with trade name Emtriva (formerly Coviracil), is a nucleoside reverse-transcriptase inhibitor (NRTI) for the prevention and treatment of HIV infection in adults and children.<unk>  is also marketed in a fixed-dose combination with tenofovir disoproxil (Viread) under the brand name Truvada, and with tenofovir alafenamide (Vemlidy) under the brand name Descovy. A fixed-dose triple combination of<unk> , tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla.<unk>  makes up one fourth of the Quad pill (brand names: Stribild and Genvoya). In fixed-dose combinations with tenofovir or with efavirenz and tenofovir it is on the World Health Organization's List of Essential Medicines. In 2017, it was the 224th most commonly prescribed medication in the United States, with more than two million prescriptions.
Emtricitabine
Letermovir
Umifenovir
Valaciclovir
Saquinavir
Balapiravir
Entecavir
Rovafovir etalafenamide